Bi-Cheng Liu
Editor

2025

Renal anemia is one of the most common complications in patients with chronic renal insufficiency. It not only affects the patient’s quality of life but also induces high mortality and socioeconomic burden. In the past few decades, the treatment of renal anemia has been significantly shaped by the emergence of human recombinant erythropoietin and iron supplements, the former is also called as erythropoietinstimulating agents (ESAs).